Skip to Main Content

Paper Details

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.
Ann Oncol
23
2023
Author NameAffiliation
Kim N ChiUniversity of British Columbia
Gerhardt AttardUniversity College London Cancer Institute, UK University College London Hospitals
Eric J SmallHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
Dana E RathkopfMemorial Sloan Kettering Cancer Center
Eleni EfstathiouHouston Methodist Cancer Center
  • 1 - 5

Datasets